摘要
1例69岁男性膀胱尿路上皮癌患者,因下肢深静脉血栓于1个半月前口服华法林钠片3mg·d^(-1)。此次患者为接受吉西他滨联合顺铂化疗入院,入院时检测患者INR 5.15,无出血表现。为防止发生出血事件,遂将华法林钠片剂量减至2.5mg·d^(-1)。第一次化疗时患者INR降至4.74,化疗后INR回升至6.04。其后每次化疗后1～2 d患者INR均有所升高。总体波动程度在0.5～1.3之间,化疗后一周左右复查,患者INR回落。结束最后一次化疗后的第6天患者INR降至1.85。整个化疗过程中患者未发生出血事件。
A 69-year-old male patient with bladder urothelial carcinoma took warfarin (3 mg, qd) one and a half month ago because of developing deep venous thrombosis of lower extremities. The patient was admitted to the hospital for taking chemotherapy with gemcitabine and cisplatin. On admission, the patient's INR value was 5.15 without bleeding. And the dose of warfarin was reduced to 2.5 mg once daily to avoid bleeding event. His INR decreased to 4.74 before the first chemotherapy and raised to 6.04 after the first chemotherapy. After then his INR values always raised 1 to 2 days after chemotherapy with a fluctuation from 0.5 to 1.3 and dropped about one week later. The INR value dropped to 1.85 on the 6th day after the last chemotherapy. There were no bleeding events during the whole course of chemotherapy.
作者
朱孔彩
薛文瑞
ZHU Kong-cai;XUE Wen-rui(Department of Pharmacy, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China;Department of Urology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China)
出处
《中国药物应用与监测》
CAS
2019年第2期116-118,共3页
Chinese Journal of Drug Application and Monitoring
基金
"中国初级卫生保健基金会-佑安肝病艾滋病"基金-中青年人才孵育项目(YNKTQN20180212)
